Cera Sanitaryware eyes 18-20% FY27 growth as Morbi rivals stumble; faucetware leads at 24%
Cera posted 11% YoY revenue growth in Q4FY26 with faucetware up 24% and now contributing 43% of sales. Management guides 18-20% FY27 growth, backed by 12-16% price hikes, capacity expansion from 4.3L to 5L pieces/month, and a ₹150 cr greenfield plant. Subsidiaries Senator and Polipluz to scale from ₹19 cr to ₹70-80 cr.
What happened
Cera Sanitaryware sees turnaround with 11% Q4FY26 growth as Morbi competitors face cost pressures. Faucetware leads at 24% growth; company guides 18-20% FY27
Key facts
- 11% YoY revenue growth Q4FY26
- faucetware 24% YoY growth
- faucetware 43% of Q4FY26 revenue
- sanitaryware 46% of revenue
- capacity expansion 4.3L to 5L pieces/month
- Senator+Polipluz ₹70-80 cr FY27 vs ₹19 cr FY26
- 12% sanitaryware price hike
- 16% faucetware price hike
- FY27 guidance 18-20% revenue growth
- Ebitda margin 13% FY26 +50-100 bps
- ₹150 cr greenfield plant phase 1
- stock +10% in past month
Why this matters
Morbi's stumble opens a rare M&A window in faucetware and tier-2 sanitaryware brands—Senator/Polipluz integration playbook gives Cera a template to bolt on distressed peers cheaply.
Also reported by
- Mint · Markets — 2h after first sighting